TALON

Actively Recruiting // Age-related Macular Degeneration // Clinical Trials // Michael Altaweel // Neovascular AMD // Sep 28 2020

A 64-Week, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-To-Control Regimen in Patients with Neovascular Age-Related Macular Degeneration (TALON)

  • Sponsor: Novartis Pharmaceuticals¬†
  • Principal Investigator: Michael Altaweel, MD
  • Study Coordinator: Angie Adler

Study objective:

To evaluate the efficacy and safety of brolucizumab in treatment of patients with neovascular age-related macular degeneration.

Study design:

Three 4-week injections and one 8-week injection followed by Treat-to-Control therapy from Week 16 up to Week 60/62.

Inclusion criteria:

  • Male or female patients ‚Č• 50 years of age at screening who are treatment naive
  • Active choroidal neovascularization (CNV) secondary to AMD that affects the central subfield, including retinal angiomatous proliferation (RAP) with a CNV component, confirmed by presence of active leakage from CNV seen by fluorescein angiography and sequellae of CNV, e.g. pigment epithelial detachment (PED), subretinal or sub-retinal pigment epithelium (sub-RPE) hemorrhage, blocked fluorescence, macular edema (study eye)
  • Presence of intraretinal fluid (IRF) or subretinal fluid (SRF) that affects the central subfield, as seen by Spectral Domain Optical Coherence Tomography (SD-OCT) (study eye)
  • Best-corrected visual acuity (BCVA) score between 83 and 38 letters (20/25 to 20/200), inclusive, using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at both screening and baseline visit (study eye)

Exclusion criteria:

  • Ocular conditions/disorders at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require planned medical or surgical intervention during the first 12-month study period, structural damage of the fovea, atrophy or fibrosis at the center of the fovea (study eye)
  • Any active intraocular or periocular infection or active intraocular inflammation, at screening or baseline (study eye)
  • Uncontrolled glaucoma defined as intraocular pressure (IOP) > 25 mmHg on medication, or according to investigator’s judgment, at screening or baseline (study eye)
  • Ocular treatments: previous treatment with any anti-vascular endothelial growth factor (VEGF) drugs or investigational drugs, intraocular or periocular steroids, macular laser photocoagulation, photodynamic therapy, vitreoretinal surgery, intraocular surgery (study eye)
  • Stroke or myocardial infarction during the 6-month period prior to baseline
  • Systemic anti-VEGF therapy

Contact Angie Adler with questions, 608-265-7557. For more information about this study: visit clinicaltrials.gov